from Breakingviews:

Deal junkie Valeant shoots up on $10 bln fix

February 23, 2015

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Drugmakers unlikely candidates for next big short

February 11, 2015

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Pfizer’s generics injection lifts mood for breakup

February 5, 2015

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Shire gambles AbbVie break fee on risky $5 bln deal

January 12, 2015

By Neil Unmack

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Review: An Icelandic tycoon’s sorry saga

December 19, 2014

By Quentin Webb

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Merck bets $8.4 bln on more profitable antibiotics

December 8, 2014

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Pharma’s dying assets lack M&A remedy

December 5, 2014

By Neil Unmack

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

AstraZeneca struggles to advance value defence

November 18, 2014

By Neil Unmack

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Valeant’s activist deal too clever by half

November 18, 2014

By Richard Beales and Robert Cyran

The authors are Reuters Breakingviews columnists. The opinions expressed are their own. 

from Breakingviews:

LabCorp deal tests positive for value destruction

November 3, 2014

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.